Tygacil Articles
US FDA should require Black Box warning for Pfizer’s antibiotic Tygacil, says Public Citizen
31 October 2011
Novartis to pay up to $485 million for Paratek’s IV antibiotic
12 October 2009
FDA appros new use for Wyeth's Tygacil
30 March 2009
Analysts expect profit for Theravance in 2012
2 March 2009
Rib-X
15 December 2008
EMEA's PDCO thumbs-up to eight PIPs
3 November 2008
US and UK Prix Galien awards 2008, winners announced
6 October 2008
Rib-X starts Ph II trial of RX-3341 in cSSSI
21 July 2008
Wyeth's Tygacil gets FDA "appro" letter
9 June 2008
Wyeth withdraws US CAP Tygacil application
5 May 2008
Wyeth submits Tygacil sNDA for CAP
29 October 2007
Wyeth sets sights on Japanese market
15 October 2007
Wyeth to submit Tygacil sNDA for CAP
23 July 2007
Need for drugs to tackle "superbugs"
18 June 2007
MRSA increases for sixth year running in EU hospitals
18 December 2006
Italian drug spending rises 9.2%
20 November 2006
Wyeth's Tygacil comparable to J&J's Levaquin
9 October 2006
UPDATE: ICAAC 2006 sees strong data on next-gen antibiotics: Tygacil, ceftaroline, cethromycin
9 October 2006
Wyeth's revenues hit $5.2B for 1st-half 2006
31 July 2006
Wyeth's antibiotic Tygacil launched in UK
24 July 2006
Wyeth's Tygacil cleared in European Union
15 May 2006
Wyeth's Tygacil gets nod from EMEA's CHMP
13 March 2006
Wyeth opens Ireland biotech production unit
19 September 2005
Enbrel drives Wyeht's 2nd-qtr sales
1 August 2005
FDA OKs Wyeth's novel antibiotic Tygacil
27 June 2005
Wyeth 1st-qtr earnings rocket 44%
25 April 2005
Fen-phem charges gouge Wyeth results
7 February 2005
Wyeth looking for global approval of Tygacil
20 December 2004
Wyeth mulling future of tigecycline?
28 January 2002
Showing 1-32 of 32 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
